Advanced Pharmaceutical Analysis Center
First written in FY2018. 7 of 12 entries say "Advanced", first in FY2023. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「In the active pharmaceutical ingredient sales business, capital expenditures of ¥101.626 million were made. This was primarily due to capital expenditures and other investments at コーア商事株式会社 aimed at improving analytical capabilities.」
Regarding the enhancement of pharmaceutical analytical capabilities, capital expenditures of ¥101.626 million were made in the fiscal year ending June 2026 to improve analytical capabilities. - 2026-08-07AdvancedEarnings presentation
「Renovation of the Yokohama Pharmaceutical Analysis Center」
The renovation of the Yokohama Pharmaceutical Analysis Center is positioned as growth investment in the active pharmaceutical ingredients segment and is specified as an investment item in the company’s cash allocation. - FY2026-H1Additional consideration of an upgrade to the Yokohama Pharmaceutical Analysis CenterAnnual report
「During the fiscal year, the company proceeded with consideration of an upgrade to the Yokohama Pharmaceutical Analysis Center in the active pharmaceutical ingredient sales business to strengthen its business base and address increased transaction volume and aging facilities.」
It newly indicated that consideration of an upgrade to the Yokohama Pharmaceutical Analysis Center is under way to address increased transaction volume and aging facilities as part of the enhancement of pharmaceutical analytical capabilities. - FY2025AdvancedAnnual report
「In the active pharmaceutical ingredient sales business, capital expenditures of ¥70.733 million were made. This was primarily due to capital expenditures and other investments at コーア商事株式会社 aimed at improving analytical capabilities.」
In addition to using the Osaka Pharmaceutical Analysis Center and other facilities, capital expenditures of ¥70.733 million were made in the fiscal year ending June 2025 to improve analytical capabilities. - FY2025-H1AdvancedAnnual report
「In the active pharmaceutical ingredient sales business, the company is proceeding with the use of the Osaka Pharmaceutical Analysis Center, which underwent renovation in the previous fiscal year, to accommodate further growth in transaction volume.」
Regarding the Osaka Pharmaceutical Analysis Center, it states that the company has moved from carrying out renovation work in the previous fiscal year to using the upgraded facilities to accommodate growth in transaction volume. - FY2024-Q3AdvancedAnnual report
「Renovation work was carried out at the Osaka Pharmaceutical Analysis Center to accommodate further expansion of transactions in the active pharmaceutical ingredient sales business.」
It states that renovation work was carried out to upgrade the Osaka Pharmaceutical Analysis Center and accommodate expanded transactions. - FY2024-Q2RestatedAnnual report
「We are proceeding with renovation work at the Osaka Pharmaceutical Analysis Center to accommodate further expansion of business.」
The continued progress of renovation work at the Osaka Pharmaceutical Analysis Center has been reconfirmed. - FY2024-Q1AdvancedAnnual report
「We are proceeding with renovation work at the Osaka Pharmaceutical Analysis Center to accommodate further expansion of business.」
Regarding the enhancement of pharmaceutical analysis capabilities, the company has specified that renovation work at the Osaka Pharmaceutical Analysis Center is under way to accommodate further business expansion. - FY2023AdvancedAnnual report
「We are currently expanding the testing equipment at the Osaka Pharmaceutical Analysis Center and taking steps to accommodate an increase in newly adopted products.」
Regarding the enhancement of pharmaceutical analysis capabilities, the company has specified that it is currently expanding the testing equipment at the Osaka Pharmaceutical Analysis Center. - FY2021Specification of new equipment installationAnnual report
「We will continue to focus group resources on enhancing pharmaceutical analysis capabilities, including through the installation of new equipment, and work to expand the performance of the active pharmaceutical ingredient import trading business.」
In addition to enhancing pharmaceutical analysis capabilities, the company explicitly identifies the installation of new equipment as a specific measure. - FY2019RestatedAnnual report
「We will continue to focus group resources on enhancing pharmaceutical analysis capabilities and, in turn, expanding the performance of the active pharmaceutical ingredient import trading business.」
The company has reaffirmed its policy of making focused resource investments in the pharmaceutical analysis center. - FY2018First statedAnnual report
「We will continue to focus group resources on enhancing pharmaceutical analysis capabilities and, in turn, expanding the performance of the active pharmaceutical ingredient import trading business.」
A measure to increase the value added beyond the functions of a trading company through focused investment in analytical equipment and specialized personnel.